HomeNewsBusinessEconomySerum Institute of India to invest 240 million pounds in UK: Boris Johnson's Office

Serum Institute of India to invest 240 million pounds in UK: Boris Johnson's Office

The announcement comes a couple of hours ahead of a virtual bilateral summit between Prime Minister Narendra Modi and his British counterpart Boris Johnson. SII is already running phase 1 trials of its new one dose nasal vaccine in the UK, which may be produced in the country once approved.

May 04, 2021 / 09:38 IST
Story continues below Advertisement
SII CEO Adar Poonawalla said in an interview that he was under extreme duress after being pressurised for giving priority access to vaccines to unnamed political leaders
SII CEO Adar Poonawalla said in an interview that he was under extreme duress after being pressurised for giving priority access to vaccines to unnamed political leaders

The Serum Institute of India (SII) will be investing 240 million pounds in the United Kingdom through the opening of a new sales office, British Prime Minister Boris Johnson's Office announced late on May 3 in an official statement. The investment is a part of a large tranche of over 533 million pounds of new Indian investment into the UK, expected to create 6,500 jobs in sectors such as health and technology, it said.

The announcement comes hours ahead of Prime Minister Narendra Modi's digital summit with Johnson on May 4. SII CEO Adar Poonawalla is currently in London. In an interview with the Financial Times, he has claimed to be under extreme duress after being pressurised for giving priority access to vaccines to unnamed political leaders. While Poonawalla hinted that SII might expand its manufacturing imprint beyond India, the official statement on May 4 did not mention it directly.

Story continues below Advertisement

"The sales office is expected to generate new business worth over $1 billion, £200 million of which will be invested into the UK. Serum’s investment will support clinical trials, research & development and possibly manufacturing of vaccines. This will help the UK and the world to defeat the coronavirus pandemic and other deadly diseases," the statement said.

However, it added that SII had already started phase one trials in the UK of a one-dose nasal vaccine for coronavirus, in partnership with Codagenix INC. This is expected to be produced in the UK itself if approved, experts have said.